Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors

International Journal of Gynecological Pathology

Volumn 15, Issue 1, 1996, Pages 39-44

  Marcelli, Anna R ^a   Demopoulos, Rita I ^a   Goswami, Sunanda ^a   Mittal, Khush R ^a  

^a BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

MIB1; Ovary; p53; Serous tumors of borderline malignancy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; PROTEIN P53; TUMOR ANTIGEN;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; PRIORITY JOURNAL;

EID: 0030041663     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199601000-00007     Document Type: Article

References (33)

1. Puls LE, Powell DE, De Priest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
2. Gallion HH, Powell DE, Morrow JK, et al. Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol 1992;47:137-42.
3. Katzenstein A, Mazur MT, Morgan TE, Ming-Shiao Kao. Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol 1973;2:339-53.
4. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
5. Scully RE. Ovarian tumors. A review. Hum Pathol 1977;87:686-720.
6. Russell P. Surface epithelial-stromal tumors of the ovary. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. 4th ed. 3rd rev. New York: Springer-Verlag, 1994:705-847.
7. Radisavljevic SV. The pathogenesis of ovarian cysts and cystomas. Obstet Gynecol 1977;49:424-9.
8. Hertig AT, Gore HM. Ovarian cystomas of germinal epithelial origin. A histogenetic classification. Rocky Mountain Med J 1958;55:47-50.
9. McKay DG. The origin of ovarian tumors. Clin Obstet Gynecol 1962;5:1181-98.
10. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993;2:59-63.
11. van Niekerk CC, Boerman OC, Ramaekers FCS, Poels LG. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am J Pathol 1991;38:455-63.
12. Mittal KR, Goswami S, Demopoulos RI. Immunohistochemical profile of ovarian inclusion cysts in patients with and without ovarian carcinoma. Histochem J (in press).
13. Gusberg SB, Deligdisch L. Ovarian dysplasia. A study of identical twins. Cancer 1984;54:1-4.
14. Deligdisch L, Gil J. Characterization of ovarian dysplasia by interactive morphometry. Cancer 1989;63:748-55.
15. Plaxe SC, Deligdisch L, Dottino PR, Carmel JC. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 1990;38:367-72.
16. Stenbach F. Benign, borderline and malignant serous cystadenomas of the ovary. A transmission and scanning electron microscopical study. Pathol Res Pract 1981;172:58-72.
17. Hall PA, Levison DA. Assessment of cellular proliferation in histological material. J Clin Pathol 1992;43:184-92.
18. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of Ki-67 antigen in fixed and wax embedded sections with the monoclonal antibody M1b 1. Histopathology 1993;22:355-60.
19. Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol 1992;66:4757-62.
20. Seiter H, Montenarh M. The emerging picture of p53. Int J Biochem 1994;26:145-54.
21. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990;249:104.
22. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half life. Mol Cell Biol 1988;8:531-9.
23. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in ovarian cancer. Cancer Research 1991;51:2979-84.
24. Klemi PJ, Takahashi S, Joensuu H, Kiilholma Narimalsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-33.
25. Berchuck A, Kohler M, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-6.
26. Kupryjanczyk J, Bell DA, Yendell DW, Scully RE, Thor AN. p53 expression in ovarian borderline tumors and Stage I carcinoma. Am J Clin Pathol 1994;102:671-6.
27. Tsao SW, Mok CH, Kiyotaka O, et al. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. Anticancer Res 1991;1:975-82.
28. Battifora, H. P53 Immunohistochemistry: a world of caution. [Editorial]. Hum Path 1994;25:435-7.
29. Oyasu R, Nan Li, Szumel RC, Kawamata H, Hirohashi S. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single strand conformation polymorphism. Mod Pathol 1995;8:170-6.
30. Tsuda H, Hirohashi S. Frequent occurrence of p53 gene mutations in uterine cancer at advanced clinical stage with aggressive histological phenotypes. Jpn J Cancer Res 1992;83:1184-91.
31. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
32. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993;169:425-30.
33. Yamada K, Ohkawa K, Joh K. Monoclonal antibody, MAb 12C3, is a sensitive immunohistochemical marker of early malignant change in epithelial ovarian tumors. Am J Clin Pathol 1995;103:288-94.